Packages range from $159 for basic hydration to $799 for NAD+
Adv Pediatr 33:95126 Gretz N, Manz F, Augustin R, Barrat TM, Bender-Gotze C, Brandis M, Bremer HJ, Brodehl J, Broyer M, Bulla M, Callis L, Chantler C, Diekmann L, Dillon MJ, Egli F, Ehrich JH, Endres W, Fanconi A, Feldhoff C, Geisert J, Gekle D, Gescholl-Bauer B, Grote K, Gruttner R, Hagge W, Haycock CB, Hennemann H, Klare B, Leupold D, Lohr H, Michalk D, Oliveira A, Ott F, Pistor K, Rau J, Scharer K, Schindera F, Schmidt H, Schulte-Wissermann H, Verrier-Jones K, Weber HP, Willenbockel U, Wolf H (1983) Survival time in cystinosis
AnaptysBio is developing its own wholly owned PD-1 agonist candidate for rheumatoid arthritis, rosnilimab, with data expected in Q1 2025
Briassoulis G, Filippou O, Kanariou M, Papassotiriou I, Hatzis T